Frederick Howard to Humans
This is a "connection" page, showing publications Frederick Howard has written about Humans.
Connection Strength
0.567
-
Generative adversarial networks accurately reconstruct pan-cancer histology from pathologic, genomic, and radiographic latent features. Sci Adv. 2024 Nov 15; 10(46):eadq0856.
Score: 0.032
-
ASO Author Reflections: Breast-Conserving Surgery After Neoadjuvant Systemic Therapy for Early-Stage Breast Cancer: Quantitative Biomarkers and Disparities in the Precision-Medicine Era. Ann Surg Oncol. 2024 Dec; 31(13):8904-8905.
Score: 0.032
-
Quantitative Biomarkers, Genomic Assays, and Demographics Associated with Breast-Conserving Surgery Following Neoadjuvant Therapy in Early-Stage, Hormone Receptor-Positive, HER-Negative Breast Cancer. Ann Surg Oncol. 2024 Dec; 31(13):8829-8842.
Score: 0.032
-
Characterizing the Increase in Artificial Intelligence Content Detection in Oncology Scientific Abstracts From 2021 to 2023. JCO Clin Cancer Inform. 2024 May; 8:e2400077.
Score: 0.031
-
Validation of the RSClin risk calculator in the National Cancer Data Base. Cancer. 2024 Apr 15; 130(8):1210-1220.
Score: 0.030
-
Classification of Breast Cancer According to ERBB2 Immunohistochemistry Scores-Reply. JAMA Oncol. 2023 09 01; 9(9):1299-1300.
Score: 0.030
-
Clinicopathologic Characteristics and Prognosis of ERBB2-Low Breast Cancer Among Patients in the National Cancer Database. JAMA Oncol. 2023 04 01; 9(4):500-510.
Score: 0.029
-
The evolving therapeutic landscape of antibody-drug conjugates in breast cancer. Expert Rev Anticancer Ther. 2022 12; 22(12):1325-1331.
Score: 0.028
-
Multimodal deep learning: An improvement in prognostication or a reflection of batch effect? Cancer Cell. 2023 01 09; 41(1):5-6.
Score: 0.028
-
Highly accurate response prediction in high-risk early breast cancer patients using a biophysical simulation platform. Breast Cancer Res Treat. 2022 Nov; 196(1):57-66.
Score: 0.028
-
Clinical trials of immunotherapy in triple-negative breast cancer. Breast Cancer Res Treat. 2022 Aug; 195(1):1-15.
Score: 0.027
-
The emerging role of immune checkpoint inhibitors for the treatment of breast cancer. Expert Opin Investig Drugs. 2022 Jun; 31(6):531-548.
Score: 0.026
-
The impact of site-specific digital histology signatures on deep learning model accuracy and bias. Nat Commun. 2021 07 20; 12(1):4423.
Score: 0.025
-
Epidemiology of Triple-Negative Breast Cancer: A Review. Cancer J. 2021 Jan-Feb 01; 27(1):8-16.
Score: 0.025
-
Machine Learning-Guided Adjuvant Treatment of Head and Neck Cancer. JAMA Netw Open. 2020 11 02; 3(11):e2025881.
Score: 0.024
-
Implementation of an automated scheduling tool improves schedule quality and resident satisfaction. PLoS One. 2020; 15(8):e0236952.
Score: 0.024
-
Prognosis and Treatment of Non-Small Cell Lung Cancer in the Age of Deep Learning. JAMA Netw Open. 2020 06 01; 3(6):e206368.
Score: 0.024
-
Pneumococcal Bacteremia Complicated by Hemophagocytic Lymphohistiocytosis. J Gen Intern Med. 2019 08; 34(8):1653-1657.
Score: 0.022
-
Predicting pathologic complete response to neoadjuvant chemotherapy in breast cancer using a machine learning approach. Breast Cancer Res. 2024 Oct 29; 26(1):148.
Score: 0.008
-
Developing a low-cost, open-source, locally manufactured workstation and computational pipeline for automated histopathology evaluation using deep learning. EBioMedicine. 2024 Sep; 107:105276.
Score: 0.008
-
Bilateral asymmetry of quantitative parenchymal kinetics at ultrafast DCE-MRI predict response to neoadjuvant chemotherapy in patients with HER2+ breast cancer. Magn Reson Imaging. 2023 Dec; 104:9-15.
Score: 0.007
-
Molecular profiling of a real-world breast cancer cohort with genetically inferred ancestries reveals actionable tumor biology differences between European ancestry and African ancestry patient populations. Breast Cancer Res. 2023 05 25; 25(1):58.
Score: 0.007
-
The impact of race and age on response to neoadjuvant therapy and long-term outcomes in Black and White women with early-stage breast cancer. Breast Cancer Res Treat. 2023 Jul; 200(1):75-83.
Score: 0.007
-
Response to Treatment, Racial and Ethnic Disparity, and Survival in Patients With Breast Cancer Undergoing Neoadjuvant Chemotherapy in the US. JAMA Netw Open. 2023 03 01; 6(3):e235834.
Score: 0.007
-
Racial Disparities in Pathological Complete Response Among Patients Receiving Neoadjuvant Chemotherapy for Early-Stage Breast Cancer. JAMA Netw Open. 2023 03 01; 6(3):e233329.
Score: 0.007
-
Towards Patient-Specific Optimization of Neoadjuvant Treatment Protocols for Breast Cancer Based on Image-Guided Fluid Dynamics. IEEE Trans Biomed Eng. 2022 11; 69(11):3334-3344.
Score: 0.007
-
Development and Validation of a Decision Analytical Model for Posttreatment Surveillance for Patients With Oropharyngeal Carcinoma. JAMA Netw Open. 2022 04 01; 5(4):e227240.
Score: 0.007
-
Differences Between Ipsilateral and Contralateral Early Parenchymal Enhancement Kinetics Predict Response of Breast Cancer to Neoadjuvant Therapy. Acad Radiol. 2022 10; 29(10):1469-1479.
Score: 0.007